Aspartic Acid

Aspartic Acid

SCHEMBL7044236

NC=O.N[C@@H](CC(=O)O)C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SSTR1SSTR2SSTR3SSTR5

The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 12/20 0.50
GRIK2 Q13002 7/20 0.50
GRM1 Q13255 2/20 0.48
GRM2 Q14416 2/20 0.48
GRIA4 P48058 4/20 0.46
GRIK3 Q13003 4/20 0.46
GRIK5 Q16478 4/20 0.46
GRIA2 P42262 3/20 0.46
GRIA1 P42261 2/20 0.46
SLC1A1 P43005 2/20 0.46
SLC7A5 Q01650 1/20 0.46
GRM8 O00222 1/20 0.46
GRM6 O15303 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GSR P00390 1/20 0.46
CYP1A2 P05177 1/20 0.46
GRM5 P41594 1/20 0.46
GRIA3 P42263 1/20 0.46
SLC1A3 P43003 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aspartic Acid SCHEMBL27866701 1.00 GRIK1 (0.50) GRIK1GRIK2GRM1GRM2GRIA4
Aspartic Acid SCHEMBL7768957 0.90 GRIK1 (0.50) GRIK1GRIK2GRM1GRM2GRIA4
Aspartic Acid SCHEMBL11065185 0.89 GRIK1 (0.56) GRIK1GRIK2GRM1GRM2GRIA4
Aspartic Acid SCHEMBL31070222 0.89
D-Aspartate SCHEMBL31235712 0.89 GRIK1 (0.56) GRIK1GRIK2GRM1GRM2GRIA4
Aspartic Acid SCHEMBL11065189 0.89 GRIK1 (0.56) GRIK1GRIK2GRM1GRM2GRIA4
Aspartic Acid SCHEMBL3231 0.89
Aspartic Acid SCHEMBL996424 0.89 GRIK1 (0.56) GRIK1GRIK2GRM1GRM2GRIA4
Aspartic Acid SCHEMBL1526976 0.89 GRIK1 (0.56) GRIK1GRIK2GRM1GRM2GRIA4
D-Aspartate SCHEMBL145539 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113195003-B Drug delivery system using solution 国立大学法人京都大学 2024-12-31 CN claimed
US-20220023207-A1 DRUG DELIVERY SYSTEM USING SOLUTION KYOTO UNIVERSITY (JP) 2022-01-27 US claimed
EP-3888693-A1 DRUG DELIVERY SYSTEM USING SOLUTION Kyoto University (JP) 2021-10-06 EP claimed
CN-113195003-A Drug delivery system using solution 国立大学法人京都大学 2021-07-30 CN claimed
CN-101611312-A Method for screening essential metabolites in microbial growth KOREA INST SCI & TECH (KR) 2009-12-23 CN claimed
CN-113195003-B Drug delivery system using solution 国立大学法人京都大学 2024-12-31 CN disclosed
CN-118020888-A Use of dihydroorotase for reducing purine content 中国海洋大学 2024-05-14 CN disclosed
US-20230309502-A1 ANIMAL LITTER COMPOSITIONS AND METHOD OF AMMONIA ABATEMENT CONTROLLED RELEASE TECHNOLOGIES, INC. (US) 2023-10-05 US disclosed
WO-2023158815-A1 ANIMAL LITTER COMPOSITIONS AND METHOD OF AMMONIA ABATMENT CONTROLLED RELEASE TECHNOLOGIES, INC. (US) 2023-08-24 WO disclosed
US-20230056311-A1 METHOD FOR IMPROVING PRODUCTION OF STREPTOMYCES POLYKETIDE COMPOUNDS INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2023-02-23 US disclosed
US-20220023207-A1 DRUG DELIVERY SYSTEM USING SOLUTION KYOTO UNIVERSITY (JP) 2022-01-27 US disclosed
EP-3888693-A1 DRUG DELIVERY SYSTEM USING SOLUTION Kyoto University (JP) 2021-10-06 EP disclosed
CN-1314488-A New polypeptide-human dihydroorotase 13 and polynucleotide for coding such polypeptide BODE GENE DEV CO LTD SHANGHAI (CN) 2001-09-26 CN disclosed
CN-1314489-A New polypeptide-human dihydroorotase 17 and polynucleotide for coding such polypeptide BODE GENE DEV CO LTD SHANGHAI (CN) 2001-09-26 CN disclosed
CN-1312385-A Human dihydroorotase 9 as one new polypeptide and polynucleotides encoding this polypeptide BODE GENE DEV CO LTD SHANGHAI (CN) 2001-09-12 CN disclosed
CN-1311328-A New polypeptide-human dihydrooratase 23 and polynucleotide for coding such polypeptide BODE GENE DEV CO LTD SHANGHAI (CN) 2001-09-05 CN disclosed
CN-1301827-A New polypeptide-dihydrooratase 9 polynucleotide coding such polypeptide BODE GENE DEV CO LTD SHANGHAI (CN) 2001-07-04 CN disclosed
CN-1301825-A New polypeptide-human dihydrooratase 10 and polynucleotide coding such polypeptide BODE GENE DEV CO LTD SHANGHAI (CN) 2001-07-04 CN disclosed
US-6251625-B1 ENZYMATIC PREPARATION OF PROTECTED DI- OR OLIGOPEPTIDES AND REMOVAL OF THE PROTECTIVE GROUP USED BY SPLITTING OFF DEGUSSA AKTIENGESELLSCHAFT (DE) 2001-06-26 US disclosed
EP-0029000-A1 Mixed salts of an alkaline earth metal and of dimethylamino ethanol of N-acyl-glutamic acids and N-acyl-aspartic acids INTERCO S.A. (CH) 1981-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023207-A1 DRUG DELIVERY SYSTEM USING SOLUTION PDIA6, PDIA5, DUS2 GRIK1 4841/4885GRIK2 4862/4885GRM1 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.